Fusion Pharm Stock Analysis
| FSPM Stock | USD 0.0001 0.00 0.00% |
Fusion Pharm is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of Fusion Pharm stock analysis is to determine its intrinsic value, which is an estimate of what Fusion Pharm is worth, separate from its market price. There are two main types of Fusion Pharm's stock analysis: fundamental analysis and technical analysis.
The Fusion Pharm stock is traded in the USA on OTCCE Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Fusion Pharm is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Fusion Stock trading window is adjusted to America/New York timezone.
Fusion |
Fusion Stock Analysis Notes
The company recorded a loss per share of 0.15. Fusion Pharm last dividend was issued on the 27th of February 1998. The entity had 1:200 split on the 1st of March 2011. FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. The company was founded in 1998 and is based in Commerce City, Colorado. Fusion Pharm operates under Pharmaceutical Retailers classification in the United States and is traded on OTC Exchange. It employs 4 people. To learn more about Fusion Pharm call the company at 720-458-0686 or check out https://www.fusionpharminc.com.Fusion Pharm Investment Alerts
| Fusion Pharm generated a negative expected return over the last 90 days | |
| Fusion Pharm has some characteristics of a very speculative penny stock | |
| Fusion Pharm has high likelihood to experience some financial distress in the next 2 years | |
| Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 34.19 K. | |
| Fusion Pharm has a frail financial position based on the latest SEC disclosures |
Fusion Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.06 K.Fusion Profitablity
The company has Profit Margin (PM) of (1.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.24.Management Efficiency
Fusion Pharm has return on total asset (ROA) of (1.3769) % which means that it has lost $1.3769 on every $100 spent on assets. This is way below average. Fusion Pharm's management efficiency ratios could be used to measure how well Fusion Pharm manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Fusion Pharm's Other Assets are very stable compared to the past year. As of the 22nd of November 2024, Intangible Assets is likely to grow to 102.64, while Total Assets are likely to drop 3,450.Effective leadership at Fusion Pharm drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Operating Margin (1.24) | Profit Margin (1.11) | Beta 9.72 | Return On Assets (1.38) |
Technical Drivers
Fusion Pharm technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Fusion Pharm Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Fusion Pharm middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Fusion Pharm. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Fusion Pharm Outstanding Bonds
Fusion Pharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fusion Pharm uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fusion bonds can be classified according to their maturity, which is the date when Fusion Pharm has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
About Fusion Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Fusion Pharm prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fusion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Fusion Pharm. By using and applying Fusion Stock analysis, traders can create a robust methodology for identifying Fusion entry and exit points for their positions.
FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. The company was founded in 1998 and is based in Commerce City, Colorado. Fusion Pharm operates under Pharmaceutical Retailers classification in the United States and is traded on OTC Exchange. It employs 4 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Fusion Pharm to your portfolios without increasing risk or reducing expected return.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.